TNFRSF8 and T-cell non-Hodgkin lymphoma: CD30 is not only an important diagnostic and prognostic marker, but also a therapeutic target for antibody-based therapy, such as brentuximab-vedotin, which is approved for relapsed or refractory cutaneous CD30+ T-cell lymphomas, including primary cutaneous ALCL [17,20,39,59,60].